[ad_1] In Q1-Q3 2024, Ryvu recognized total operating revenues (including grants) of USD 18.6 million, compared to USD 11.9 million in Q1-Q3 2023. Ryvu reports an acceleration in patient enrollment for its RVU120 Phase II clinical studies, […]

[ad_1] The total operating revenues in H1 2024 amounted to USD 12.1 million and increased by USD 4.2 million compared to H1 2023. As of September, 5 2024, Ryvu’s cash position was USD 65.3 million. […]